"10.1371_journal.pone.0089014","plos one","2014-02-12T00:00:00Z","Claudia Duran-Aniotz; Rodrigo Morales; Ines Moreno-Gonzalez; Ping Ping Hu; Joseph Fedynyshyn; Claudio Soto","Mitchell Center for Alzheimers Disease and Related Brain Disorders, Department of Neurology, University of Texas Houston Medical School, Houston, Texas, United States of America; Universidad de los Andes, Facultad de Medicina, Santiago, Chile; Education Ministry Key Laboratory on Luminescence and Real-Time Analysis, College of Life Sciences, Southwest University, Chongqing, China; Novartis Vaccines and Diagnostics, Emeryville, California, United States of America","Conceived and designed the experiments: CD-A RM CS. Performed the experiments: CD-A RM IM-G PPH. Analyzed the data: CD-A RM IM-G CS. Contributed reagents/materials/analysis tools: JF. Wrote the paper: CD-A RM IM-G CS.","This study was funded by a grant from Novartis Vaccines and Diagnostics, which owns the rights to commercialize the use of the ASR1 reagent. Dr. Soto served as Scientific Consultant for Novartis Vaccines and Diagnostics during the time in which the project was performed. Dr. Fedynyshyn was employed by the company during the first part of the work, but is no longer employed by Novartis. Dr. Fedynyshyn is an inventor on the patents related to the ASR-1 technology: Amyloid Beta Aggregates in Cerebro Spinal Fluid as Biomarker for Alzheimers Disease. PCT/US2010/058450. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2014","02","Claudia Duran-Aniotz","CDA",6,TRUE,3,4,4,4,TRUE,TRUE,FALSE,0,NA,FALSE
